Noninfectious pulmonary complications of HIV/AIDS

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 3, 2005, Pages 208-212

  Kanmogne, Georgette D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cancer; Complications; Highly active antiretroviral therapy; HIV AIDS; Pulmonary pulmonary hypertension

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER GROWTH; CANCER RISK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; KAPOSI SARCOMA; LUNG CANCER; LUNG DISEASE; LYMPHOMA; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; SURVIVAL;

EID: 17744365034     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcp.0000159833.28271.00     Document Type: Review

References (54)

1. Afessa B, Green W, Chiao J, Frederick W. Pulmonary complications of HIV infection: autopsy findings. Chest 1998; 113:1225-1229.
2. Masliah E, DeTeresa RM, Mallory ME, Hansen LA. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 2000; 14:69-74.
3. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41:1-19.
4. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of HIV-infected patients. J Clin Oncol 2003; 21:3447-3453.
5. Powles T, Thirwell C, Newsom-Davis T, et al. Does HIV adversely influence the outcome in advanced non-small-cell lung cancer in the era of HAART? Br J Cancer 2003; 89:457-459.
6. Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer 2003; 89:94-100.
7. Demopoulos BP, Vamvakas E, Ehrlich JE, Demoloulos R. Non-AIDS-defining malignancies in patients infected with HIV. Arch Pathol Lab Med 2003; 127:589-592.
8. Allardice GM, Hole DJ, Brewster DH, et al. Incidence of malignant neoplasms among HIV-infected persons in Scotland. Br J Cancer 2003; 89:505-507.
9. Powles T, Nelson M, Bower M. HIV-related lung cancer: a growing concern? Int J STD AIDS 2003; 14:647-651.
10. Bower M, Powles T, Nelson M, et al. HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS 2003; 17:371-375.
11. Chiao EY, Krown SE. Update on non-AIDS-defining malignancies. Curr Opin Oncol 2003; 15:389-397.
12. Cailhol J, Calatroni MI, Roudiere L, et al. Increased incidence of lung neoplasms among HIV-infected men and the need for improved prevention. J Acquir Immune Defic Syndr 2003; 34:247-249.
13. Lewden C, Salmon D, Morlat P et al. Causes of death among HIV-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. Advance Access published November 23, 2004. Large prospective cohort study showing the emerging role of cancers as important causes of death in HIV-positive patients in the HAART era.
14. Burke M, Furman A, Hoffman M, et al. Lung cancer in patients with HIV infection: is it AIDS-related? HIV Med 2004; 5:110-114.
15. Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in HIV-infected patients in the era of highly active antiretroviral therapy. Cancer 2004; 101:317-324. Large prospective cohort study showing the emerging role of cancers as important causes of death in HIV-positive patients in the HAART era.
16. Spano JP, Massiani MA, Bentata M, et al. Lung cancer in patients with HIV infection and review of the literature. Med Oncol 2004; 21:109-115.
17. Hessol NA, Seaberg EC, Preston-Martin S, et al. Cancer risk among participants in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 36:978-985.
18. Biggar RJ, Kirby KA, Atkinson J, et al. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004; 36:861-868.
19. Kanmogne GD, Kennedy RC, Grammas P. Is HIV involved in the pathogenesis of non-infectious pulmonary complications in infected patients? Curr HIV Res 2003; 1:385-393.
20. Dezube BJ, Pantanowitz L, Aboulafia DM. Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read 2004; 14:236-238 243-244, 251-253.
21. Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17:F17-F22.
22. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22: 399-402.
23. Stebbing J, Bower M. What can oncologists learn from HIV. Lancet Oncol 2003; 4:438-445.
24. Aboulafia DM, Pantanowitz L, Dezube BJ. AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART. AIDS Read 2004; 14:605-617. Excellent review of the epidemiology, pathology, pathogenesis, clinical features, and treatment of AIDS-related NHL in the HAART era.
25. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003; 32:527-533.
26. Thirlwell C, Sarker D, Stebbing J, Bower M. AIDS-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma 2003; 4:86-92.
27. Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004; 22:2177-2183. Interesting study showing that different HAART regimens protect against AIDS-related NHL.
28. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of AIDS-related with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4853-4859.
29. Ratner L, Lee J, Tang S, et al. Chemotherapy for HIV-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19:2171-2178.
30. Powles T, Imami N, Nelson M, et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-associated lymphoma. AIDS 2002; 16:531-536.
31. Mehta NJ, Khan IA, Mehta RN, et al. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118:1133-1141.
32. Valencia Ortega ME, Ortega Millan G, Guinea Esquerdo J, et al. Pulmonary hypertension in patients with HIV infection: study of 14 cases. Med Clin (Barc) 2000; 115:181-184.
33. Eulalia Valencia M, Guinea J, Moreno V, Gonzalez-Lahoz J. Severe pulmonary hypertension treated with low dose carvedilol in a patient infected with HIV. Enferm Infecc Microbiol Clin 2001; 19:512-513.
34. Dawson DG, Johnson MW. Ciliochoroidal effusion and pulmonary hypertension in a patient with HIV infection. Retina 2001; 21:672-674.
35. Speich R, Jenni R, Opravil M, Jaccard R. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly 2001; 131:663-665.
36. Leautez S, Boutoille D, Renard B, et al. Pulmonary hypertension in HIV-infected patients. Rev Mal Respir 2001; 18:432-435.
37. Le Houssine P, Karmochine M, Ledru F, et al. Primary pulmonary hypertension in HIV infection: study of 9 cases and review of the literature. Rev Med Interne 2001; 22:1196-1203.
38. Almeida L, Amado P, Santos I, et al. Pulmonary hypertension. Topic review: 2 clinical cases. Rev Port Cardiol 2002; 21:173-180.
39. Niakara A, Drabo YJ, Kambire Y, et al. Cardiovascular diseases and HIV infection: study of 79 cases at the National Hospital of Ouagadougou (Burkina Faso). Bull Soc Pathol Exot 2002; 95:23-26.
40. Hourseau M, Capron F, Nunes H, et al. Pulmonary veno-occlusive disease in a patient with HIV infection: a case report with autopsy findings. Ann Pathol 2002; 22:472-475.
41. Martinez Torres MA, Pavon Jimenez R, Corzo Delgado J, Pastor Torres L. Pulmonary hypertension associated with HIV infection: a review of 4 cases. Rev Esp Cardiol 2002; 55:673-677.
42. Bugnone AN, Viamonte M Jr, Garcia H. Imaging findings in HIV-related pulmonary hypertension: report of five cases and review of the literature. Radiology 2002; 223:820-827.
43. Alp S. Long-term survival with HIV-related pulmonary arterial hypertension: a case report. AIDS 2003; 17:1714-1715.
44. Nunes H, Humber M, Sitbon O, et al. Prognostic factors for survival in HIV-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167:1433-1439.
45. Ball SC. Pulmonary hypertension and HIV. AIDS Read 2003; 13:209-210, 217-219.
46. Recusani F, Di Matteo A, Gambarin F, et al. Clinical and therapeutic follow-up of HIV-associated pulmonary hypertension: prospective study of 10 patients. AIDS 2003; 17(suppl 1):S88-S95.
47. Pai RK, Kedia A, Hsu PYF, et al. AIDS associated with severe cor pulmonale and large pericardial effusion with cardiac tamponade. Cardiol Rev 2004; 12:49-55.
48. Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38:1178-1185. This study shows that HAART decreases mortality due to HIV-related pulmonary hypertension and is beneficial for the treatment of pulmonary hypertension.
49. Klings ES, Farber HW. The pathogenesis of HIV-associated pulmonary hypertension. Adv Cardiol 2003; 40:71-82.
50. Pellicelli AM, D'Ambrosio C, Vizza CD, et al. HIV-related pulmonary hypertension: from pathogenesis to clinical aspects. Acta Cardiol 2004; 59:323-330.
51. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004; 109:159-165. An excellent review of the role of endothelial cells in the pathogenesis of pulmonary hypertension. The authors use evidence from published studies to propose hypotheses on the pathogenic mechanisms by which endothelial cell dysfunction leads to the development of pulmonary hypertension.
52. Kanmogne GD, Kennedy RC, Grammas P. Analysis of human lung endothelial cells for susceptibility to HIV type 1 infection, coreceptor expression and cytotoxicity of gp120 protein. AIDS Res Hum Retroviruses 2001; 17:45-53.
53. Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85:504-509.
54. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.